Table 4 Comparison of clinical and analytical characteristics between children with poor (< 90%) and adequate adherence (> 90%)

Opportunistic infections during follow-up

10/41 (24.4%)

10/18 (55.6%)

0.02

Clinical stage N/A during follow-up

20/39 (51.3%)

0/16 (0%)

< 0.01

Clinical stage C during follow-up

15/40 (37.5%)

15/17 (88.2%)

< 0.01

Immunological stage 3 throughout follow-up

5/34 (14.7%)

8/12 (66.7%)

< 0.01

Pathological psychomotor development during follow-up

7/42 (16.7%)

5/17 (29.4%)

0.27

CD4 cells at check-up 4 (cells/µl)

Median (IQR), n = 54

1086 (511)

1175 (758)

0.85

CD4 percentage at check-up 4

Median (IQR), n = 25

34.7% (10.6%)

32.5% (16.1%)

0.42

CD4/CD8 ratio at check-up 4

Median (IQR), n = 25

0.97 (0.49)

0.69 (1.04)

0.7

Viral load at check-up 4 (copies/ml)

Median (IQR), n = 57

40 (40)

40 (2395)

0.06

Viral load < 50 copies/ml at check-up 4

8/39 (20.5%)

7/18 (38.9%)

0.14

Toxicity during follow-up

7/42 (16.7%)

1/17 (5.9%)

0.27

Psychosocial care during follow-up

37/42 (88.1%)

17/19 (89.5%)

0.88

Hospitalization during follow-up

10/42 (23.8%)

6/17 (35.5%)

0.37

Deaths during follow-up

1/42 (2.4%)

0/17 (0%)

0.71